Drug Resistance (HIV)

HIV Genotyping Program To Maximize Drug Treatment Announced

Published in AIDS Weekly, November 23rd, 1998

Visible Genetics Inc. (VGI), Toronto, Ontario, Canada, has launched a comprehensive educational program entitled "Vigilance in Europe" to demonstrate and establish the clinical utility of genotyping in HIV management.

The program has two parts - a clinical trial and a call for scientific projects. The trial provides free genotyping to individuals exposed to HIV; proposals from European virological and infectious diseases centers should plan to evaluate the clinical utility of HIV genotyping.

Charles A.B. Boucher, MD, PhD, University Hospital, Utrecht, The Netherlands, announced the program at a special symposium at the 4th International Congress on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry